Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 marketed 24 in Phase 3

This page covers all Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Estrogen Receptor (ER), Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα), Estrogen receptor (ER) and HER1/HER2/HER4.

Targets

Estrogen Receptor (ER) · Histone deacetylases (HDAC) + Estrogen receptor alpha (ERα) · Estrogen receptor (ER) and HER1/HER2/HER4 · Estrogen receptor · Estrogen receptor (ER) and CDK4/CDK6 · Estrogen Receptor Alpha (ERα) · CDK4/6 (palbociclib); Aromatase (letrozole) or Estrogen Receptor (fulvestrant) · Estrogen receptor (ER) + GnRH receptor · Estrogen Receptor Alpha (ESR1) · Estrogen receptor alpha (ERα)

Marketed (2)

PF-07850327, ARV-471, vepdegestrant · Pfizer · Oncology
Chidamide+ Fulvestrant · Liaoning Cancer Hospital & Institute · Oncology
Chidamide inhibits histone deacetylases to reactivate tumor suppressor genes, while fulvestrant blocks estrogen receptor signaling to inhibit hormone-dependent breast cancer growth.

Phase 3 pipeline (24)

Fulvestrant combined with Pyrotinib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Oncology
Fulvestrant blocks estrogen receptor signaling while pyrotinib inhibits HER2 tyrosine kinase, together targeting hormone receptor-positive and HER2-positive breast cancer through dual pathway inhibition.
faslodex dummy · AstraZeneca · Oncology
Faslodex is a selective estrogen receptor degrader (SERD) that blocks estrogen receptors in breast cancer cells.
HGP0904 · Hanmi Pharmaceutical Company Limited · Oncology
HGP0904 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
CKD-342 · Chong Kun Dang Pharmaceutical · Oncology
CKD-342 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
Fulvestrant in combination with abemaciclib · Sermonix Pharmaceuticals Inc. · Oncology
Fulvestrant blocks estrogen receptors while abemaciclib inhibits CDK4/6, together suppressing hormone-driven breast cancer cell growth through dual pathway inhibition.
DA-3002 · Dong-A ST Co., Ltd. · Oncology
DA-3002 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, eliminating both ligand-dependent and ligand-independent signaling in hormone receptor-positive breast cancer.
CKD-701 · Chong Kun Dang Pharmaceutical · Oncology
CKD-701 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
HM11260C · Hanmi Pharmaceutical Company Limited · Oncology
HM11260C is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
Physician's Choice of Endocrine Therapy · Hoffmann-La Roche · Oncology
Physician's Choice of Endocrine Therapy is a treatment that targets hormone receptors to prevent or slow the growth of cancer cells.
CKD-351 · Chong Kun Dang Pharmaceutical · Oncology
CKD-351 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
CKD-825 · Chong Kun Dang Pharmaceutical · Oncology
CKD-825 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
Palbociclib + Letrozole OR Fulvestrant · SOLTI Breast Cancer Research Group · Oncology
Palbociclib inhibits cyclin-dependent kinases 4 and 6 to block cell cycle progression, combined with either letrozole (aromatase inhibitor) or fulvestrant (estrogen receptor antagonist) to suppress hormone-driven breast cancer growth.
CKD-843 dose#1 · Chong Kun Dang Pharmaceutical · Oncology
CKD-843 is a selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-dependent signaling in hormone-sensitive cancers.
Placebo + fulvestrant · Nanjing Chia-tai Tianqing Pharmaceutical · Oncology
Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, while placebo serves as a control arm in this combination study.
Standard-of-care endocrine treatment · West German Study Group · Oncology
Blocks estrogen receptors to prevent cancer cell growth.
Placebo,Fulvestrant,Goserelin acetate · Ahon Pharmaceutical Co., Ltd. · Oncology
This combination uses fulvestrant to block estrogen receptors in cancer cells and goserelin to suppress ovarian hormone production, while placebo serves as a control arm.
GB491+ Fulvestrant · Genor Biopharma Co., Ltd. · Oncology
GB491 is a selective estrogen receptor degrader (SERD) that works synergistically with fulvestrant to degrade estrogen receptors and block estrogen signaling in hormone receptor-positive breast cancer cells.
AZD9833 · AstraZeneca · Oncology
AZD9833 is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-driven cancer cell growth.
CKD-331 · Chong Kun Dang Pharmaceutical · Oncology
CKD-331 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.
Fulvestrant Prefilled Syringe · UNICANCER · Oncology
Fulvestrant is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors in hormone receptor-positive breast cancer cells.
Fulvestrant injection ;Dalpiciclib Isethionate · Shandong Suncadia Medicine Co., Ltd. · Oncology
This combination uses fulvestrant to block estrogen receptors in breast cancer cells while dalpiciclib inhibits cyclin-dependent kinases 4 and 6 to prevent cell cycle progression.
BGB-16673 · BeOne Medicines · Oncology
BGB-16673 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.
CKD-352 · Chong Kun Dang Pharmaceutical · Oncology
CKD-352 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.
Rezvilutamide Tablets · Jiangsu HengRui Medicine Co., Ltd. · Oncology
Rezvilutamide is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.

Patent intelligence

selective estrogen receptor degrader patent landscape — aggregated cliff calendar, attackable patents, originator estates